Vshyukova Volha, Meleshko Alexander, Mihal Natalia, Aleinikova Olga
Belarusian Research Centre for Pediatric Oncology, Hematology and Immunology, 223053, Republic of Belarus, Minsk region, v. Borovlyani, Frunzenskaya st., 43, Belarus.
Leuk Res Rep. 2016 Jun 27;6:15-9. doi: 10.1016/j.lrr.2016.06.005. eCollection 2016.
•The case demonstrated a rare event of clonal heterogeneity by IKZF1 gene status in BCRABL1- ALL.•IKZF1 deletions are secondary events in ALL caused by clonal evolution during the treatment.•It's prognostic significance could be more crucial in BCR-ABL- rather than in BCR-ABL + ALL.•IKZF1 gene alterations may be determined and proved at the genome, expression and protein level.•IKZF1 deletions are suitable for MRD detection but not stable compared to Ig/TCR rearrangement.
•该病例显示了BCR-ABL1阳性急性淋巴细胞白血病（ALL）中IKZF1基因状态罕见的克隆异质性事件。
•IKZF1缺失是ALL治疗期间克隆进化导致的继发事件。
•其预后意义在BCR-ABL阴性而非BCR-ABL阳性ALL中可能更为关键。
•IKZF1基因改变可在基因组、表达和蛋白质水平上得以确定和证实。
•IKZF1缺失适用于微小残留病（MRD）检测，但与Ig/TCR重排相比不稳定。
